Oh, what a surprise! It turns out that DNA damage, a star player in the thrilling saga of tumorigenesis and tumor development, is not just sitting around. No, it’s actually quite the busybody, increasing mutation risks and throwing lavish parties in the tumor immune microenvironment (TIME) to dictate tumor progression. Who would have thought, right?

And just when you think it couldn’t get any more dramatic, enter the dynamic duo of signaling pathways: cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) and the ever-so-catchy ataxia telangiectasia-mutated protein/ataxia telangiectasia and Rad3-related protein (ATM/ATR). These two are not just any guests; they’re the life of the party, activating downstream of DNA damage and mingling with a diverse crowd of cytokines. These cytokines, not to be outdone, showcase their multifaceted functions in the anti-tumor immune response like it’s their job (because, well, it is).

So, in a plot twist that shocks absolutely no one, we find it’s crucial to dive deep into the complex TIME reshaped by our frenemies, damaged DNA and tumor-derived cytokines. Why? Because understanding this soap opera is key to developing effective tumor therapies, of course. This manuscript is like the ultimate review, connecting the dots between the DNA damage response and related cytokines in tumors, and highlighting the dual immunoregulatory roles of these cytokines like it’s revealing the season finale cliffhanger.

But wait, there’s more! We also get a sneak peek at clinical trials targeting the signaling pathways and cytokines associated with DNA damage. And because no good review ends without leaving you wanting more, we’re given future perspectives on emerging technologies. Because, obviously, the story of DNA damage and tumor progression is to be continued…